Competition for membrane receptors : Norovirus detachment via lectin attachment by Parveen, Nagma et al.
1	
Competition for membrane receptors: norovirus 
detachment via lectin attachment 
Nagma Parveen1,*, Gustaf E. Rydell2, Göran Larson3, Vesa P. Hytönen4, 
Vladimir P. Zhdanov1, 5, Fredrik Höök1*, Stephan Block1,†* 
1Department of Physics, Chalmers University of Technology, Gothenburg, Sweden 
2Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 
Sweden 
3Department of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, 
Gothenburg, Sweden 
4Faculty of Medicine and Health Technology and BioMediTech, Tampere University, Tampere, 
Finland and Fimlab Laboratories, Tampere, Finland 
5Boreskov Institute of Catalysis, Russian Academy of Sciences, Novosibirsk, Russia 
*Laboratory for Photochemistry and Spectroscopy, Department of Chemistry, KU Leuven, Leuven,
Belgium 
†Department of Chemistry and Biochemistry, Free University of Berlin, Berlin, Germany 
Keywords: norovirus–like particle, histo–blood group antigens, glycosphingolipid, lectin, supported 
lipid bilayer, competitive inhibition, release kinetics, multivalent interaction 
This is the accepted manuscript of the article, which has been published in Journal of the american chemical society. 2019, 
141(41), 16303-16311  https://doi.org/10.1021/jacs.9b06036
	 2	
Abstract 
Virus internalization into the host cells occurs via multivalent interactions, in which a single virus 
binds to multiple receptors in parallel. Because of analytical and experimental limitations this 
complex type of interaction is still poorly understood and quantified. Herein, the multivalent 
interaction of norovirus-like particles (noroVLPs) with H or B type 1 glycosphingolipids (GSLs), 
embedded in a supported phospholipid bilayer, is investigated by following the competition between 
noroVLPs and a lectin (from Ralstonia solanacearum) upon binding to these GSLs. Changes in 
noroVLP and lectin coverage, caused by competition, were monitored for both GSLs and at different 
GSL concentrations using quartz crystal microbalance with dissipation monitoring. The study yields 
information about the minimum GSL concentration needed for i) noroVLPs to achieve firm 
attachment to the bilayer prior to competition, and to ii) remain firmly attached to the bilayer during 
competition. We show that these two concentrations are almost identical for the  
H type 1–noroVLP interaction, but differ for B type 1, indicating an accumulation of B type 1 GSLs 
in the noroVLP–bilayer interaction area. Furthermore, the GSL concentration required for firm 
attachment is significantly larger for H type 1 than for B type 1, indicating a higher affinity of 
noroVLP towards B type 1. This finding is supported by extracting the energy of single noroVLP–H 
type 1 and noroVLP–B type 1 bonds from the competition kinetics, which were estimated to be 5 and 
6 kcal/mol, respectively. This demonstrates the potential of utilizing competitive binding kinetics to 





The interaction of biological nanoparticles, such as viruses, extracellular vesicles and drug 
delivery vehicles, with the plasma membrane typically involves multiple ligands and membrane 
receptors (i.e., attachment factors) either of the same or different types. The ligands belonging to the 
nanoparticles can be either fixed or mobile, whereas receptors are typically mobile within the 
membranes of host cells.1-3 Although the energy of a single ligand-receptor bond is relatively weak 
(e.g., 1–5 kcal/mol or Kd of 0.1–5 mM for polyoma- and human noroviruses binding to 
glycosphingolipids)4-7, formation of multiple bonds results in a strong enough attachment of the virus 
particles to cell membranes.8-9 Multivalent interactions of this type are most commonly investigated 
by measuring interaction kinetics at varying receptor coverage in the membrane,6, 10-11 or by inhibiting 
the interaction by addition of compounds designed to interact with the ligands on suspended 
nanoparticles.8, 12 In the particular case of virus binding, it is also common to interfere with the ligand-
receptor interaction by addition of compounds designed to bind with appreciable affinity to the cell-
membrane receptors.13-14 This approach has turned out especially interesting in the context of antiviral 
drugs15-17 as in the case of HIV-1, where it has even reached clinical applications.18 
However, in contrast to classical surface chemistry, where the formalism describing the 
interplay of adsorption and desorption under competitive conditions is well established19-21, 
competitive binding of different biological nanoparticles to cell membranes is less understood. In 
conventional surface chemistry, the adsorption sites generally reside on a firm support and the state 
of an adsorbed atom or molecule is primarily influenced via lateral interactions with neighbouring 
adsorbed atoms or molecules, while in the case of multivalent interactions on cellular membranes, 
the receptor-mediated binding can in addition be weakened by competing entities that reduce the 
concentration of mobile receptors available for binding. Such competitive binding can be utilized to 
probe the binding affinity of viruses towards different receptor-containing cell membranes.6, 15-16 
Moreover, the competitive binding may provide a better insight to the complicated pathways of 
cellular internalization of viruses, aiding the development of antiviral drugs.  
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One of the key challenges in the context of measuring competitive binding between different 
types of biomolecules is that they need to be individually identified using a unique fingerprint. Most 
methods suitable for studying biomolecular interactions probe ligand-receptor interactions using 
soluble isolated biomolecules [such as nuclear magnetic resonance (NMR) spectroscopy, isothermal 
titration calorimetry, etc.]. In contrast, surface-based methods such as for example surface plasmon 
resonance or surface quartz crystal microbalance with dissipation (QCM-D) provide platforms to 
reconstitute receptors or ligands in lipid membranes, attaining native-like environment for binding 
kinetic studies. QCM-D offers the additional opportunity to distinguish different ligand variants given 
that they contribute differently to measured changes in frequency, Df, and energy dissipation, DD, 
upon binding to the QCM sensor surface. Aided by this capacity, we recently explored competitive 
binding interactions between cholera toxin and virus-like particles (VLPs) made from SV40 virus to 
their common GM1 receptor, and demonstrated how QCM-D monitoring could be used to quantify 
the kinetics of the interaction.6 In the present work, we put emphasis on VLPs made from the major 
viral protein (VP1) of human norovirus, which is particularly interesting in this context since it has 
been hypothesized that upon infection, noroviruses increase their chance of host infection via cellular 
attachment and subsequent internalization by binding to closely resembling yet different attachment 
factors.22-23 More specifically, we made use of competitive binding between norovirus-like particles 
(noroVLPs; ~40 nm in diameter) and a lectin (i.e., a carbohydrate-binding protein; ~4.5 nm in 
diameter) extracted from the bacterium Ralstonia solanacearum, which are both capable of binding 
specifically to the glycosphingolipids (GSLs) H type 1 and B type 1.4, 24-26 Using QCM-D, we 
explored how addition of the lectin triggers release of noroVLPs from GSL-containing supported 
lipid bilayers (SLBs) and how this competition between lectins and noroVLPs for the same GSL can 
be employed to determine the affinity of the GSL-noroVLPs interaction. We also demonstrated that 
a single competitive binding experiments is sufficient to accurately quantify the minimum GSL 
concentration required for noroVLPs to remain firmly attached to the SLB and that variations in 
multivalency for GSLs with different affinity can in this way be readily identified. 
	 5	
Materials, methods, and sample preparation 
Materials. Histo-blood group antigens (HBGAs) in form of the GSLs H type 1 (M = 1.28 kDa) 
and B type 1 (M = 1.45 kDa) were isolated from total non-acid GSL fractions purified from human 
meconia, pooled according to ABO blood group, and characterized by mass spectrometry and 1H-
NMR spectroscopy.27 Partially hexahistidine-tagged noroVLPs (with diameter 40±10 nm according 
to electron microscopy images) of GII.4 strain were expressed and characterized as detailed in Koho 
et al.28 VP1 is the major viral protein of the noroVLP and binds to H type 1 or B type 1 HBGAs. 
While most studies have shown that each VP1 proteins contains at least one binding site for HBGAs29, 
a recent report provided evidence that VP1 can bind to two HBGAs in parallel, thereby suggesting 
the presence of two HBGA binding sites per VP1.30 In total, 180 copies of the VP1 protein assemble 
into a noroVLP, leading to a density of 0.035 or 0.071 HBGA binding sites per nm² on the capsid 
surface (calculating with 1 and 2 binding sites per VP1, respectively). 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and lectin from bacterium Ralstonia solanacearum (RSL) were 
purchased from Avanti Polar Lipids (USA) and Elicityl OligoTech (Crolles, France), respectively. 
The RSL lectin (having a beta-barrel structure with diameter of 4.5 nm)24 is a hexavalent fucose-
binding lectin with Kd (monovalent dissociation constant, affinity) of 1.23 ± 0.06 µM towards L-
fucose monosaccharide.24 All the materials were diluted in a degassed phosphate buffer to achieve 
desired concentrations. The phosphate buffer contained 50 mM Na2HPO4, 100 mM NaCl, pH 7.4. 
Quartz crystal microbalance with dissipation. In QCM-D measurements, a quartz crystal 
with high quality factor (typically > 106) is excited via the piezoelectric effect to vibrate mechanically 
at its resonance frequency and accompanied overtones. This shear vibration is induced and tracked 
by an electronic feedback loop, allowing for extracting information about the frequency (f) and 
dissipative losses (D) for each probed resonance peak. These resonance properties (f and D) change 
upon adsorption of material onto the QCM-D crystal. The resonance frequencies, for example, 
generally decrease upon mass increase on the QCM-D crystal, allowing for probing time-dependent 
adsorption processes with a sensitivity down to the ng/cm2 scale. Furthermore, the dissipation D is 
	 6	
the energy damping per oscillation cycle of the crystal and indicates how much vibration energy is 
dissipated during the oscillation, e.g., due to adsorption of a soft film or due to hydrodynamic 
interaction of particles adsorbed onto the QCM-D crystal. For example, thin and relatively rigid films 
like SLBs or small proteins have a fairly low additional contribution to the dissipation, while large 
nanoparticles, such as VLPs, contribute a larger increase in the dissipation as they possess a relatively 
large hydrodynamic cross-section, inducing a notable viscous friction of the VLPs with the bulk 
solution during the vibration of the QCM-D crystal; or phrased in other words, the hydrodynamic 
interaction of flat layers or nm-sized proteins with the bulk is much smaller than that of VLPs, with 
the consequence that the latter dissipate, due to frictional losses, much more energy during an 
oscillation cycle, leading to higher dissipation values in QCM-D experiments. In typical QCM-D 
experiments, shifts in the frequency and dissipation upon molecular adsorption/binding are measured 
in a time-dependent manner. 
Formulation of phospholipid vesicles. POPC (in chloroform) and either of the HBGA GSLs 
(in 1:1 chloroform:methanol, v/v) were pipetted into a round bottom flask. The lipid mixture was first 
dried under a gentle N2 stream and then dried in vacuum (2 hrs) to obtain a thin lipid film. This dried 
film was hydrated in the phosphate buffer with help of a vortex. Lipid vesicles were prepared by 
extruding (13 times) this hydrated lipid suspension with polycarbonate filter (Whatman, UK) of 30 
nm pore size. Four vesicle compositions were made by mixing desired weight ratio of POPC and 
GSLs: (i) POPC, (ii) POPC+3.5 mol% B type 1, (iii) POPC+3.9 mol% H type 1, and (iv) POPC+6.3 
mol% H type 1. The size (diameter) distribution of the extruded vesicles, determined with a 
Nanoparticle Tracking Analysis (NTA; Malvern, UK) device, exhibits one peak at about 100 nm with 
a full width at half maxima (FWHM) of 40 nm. 
Supported lipid bilayer formation. SLBs were formed by spreading phospholipid vesicles on 
a silica-coated QCM-D crystal (QSense E4 instrument; QSense, Göteborg, Sweden).31 The total GSL 
concentration, i.e., H or B type 1 content in the bilayer was regulated by using a vesicle solution, 
which was created by mixing pure POPC vesicles with POPC vesicles containing either 3.9 mol% H 
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type 1 or 3.5 mol% B type 1, respectively, until the desired mol% of GSL to the total POPC lipids 
has been reached. The only exception to this approach were SLBs containing 6.3 mol% H type 1, 
which were created using vesicles composed of 6.3 mol% H type 1 and 93.7 mol% POPC lipids. 
Further details are described in the Supporting information. 
 
Results. High quality SLB formation was verified from a non-monotonic change in QCM-D 
response with a final frequency shift (∆f) of about −28±3 Hz and dissipation shift (∆D) of 
(0.2±0.15)×10-6 upon addition of GSL-containing lipid vesicles (Figure S1 in the Supporting 
Information).31 Subsequent injection of a noroVLP suspension (Figure 1) resulted in monotonic 
decrease in ∆f (mass uptake) and increase in ∆D (damping), with diminishing rate of binding and 
saturated responses as the GSL content of the SLB was decreased, while there was no detectable 
binding to a SLB made of POPC lipids only (data not shown). This confirms that the noroVLP binding 
was specific to the presence of H or B type 1 in the SLB. The overall attachment appeared to be 
irreversible (upon washing with buffer) on SLBs with GSL concentrations exceeding 
3.9 mol% H type 1 or 0.7mol% B type 1. This is an indication of multivalent binding of the virus at 
high GSL density resulting in a firm attachment of the virus on SLB. This conclusion is further 
supported by the non-linear transition of the initial binding rate (d∆f/dt) of the noroVLP, which at a 
constant noroVLP concentration showed an inflection point at around 3 mol% H type 1 and 0.5 mol% 
B type 1, respectively, and a saturation behavior of the binding rate at larger GSL concentrations 
(Figure 1d). This transition indicates that the noroVLP binding is reaction-limited below 3 mol% H 
type 1 and 0.5 mol% B type 1, respectively. Above these concentrations, the diffusion of noroVLPs 
to the SLB controls the virus binding kinetics. This binding behavior is in agreement with previous 
studies that showed a similar transition in the binding rate at around 3 mol% H type 1 for the GII.4 




Figure 1. Binding of noroVLPs to a supported lipid bilayer. (a) Left: Schematics of the competitive 
binding experiments. Right: Chemical composition of H and B type 1 GSLs. The ceramide tail of the 
GSLs has a heterogeneous composition but it is similar for H and B type 1 as they are extracted from 
the same natural source. QCM-D time-traces (seventh overtone) upon noroVLP and subsequent lectin 
binding to SLBs with total (b) H type 1 concentration ranging from 2.8 to 6.3 mol% and (c) B type 1 
concentration ranging from 0.4 to 3.5 mol% (as indicated in the plots). The black and green lines 
correspond to the frequency and dissipation shift, respectively. The arrows indicate the starting 
moments of solution exchange (the time to reach the measurement chamber was ~4 min at the flow 
speed used). The binding curves were measured upon subsequent injections of 0.25 nM noroVLP, 
pure buffer, and lectin at a flow rate of 25 µl/min. 8 nM lectin was used in case of 3.9 mol% H type 
1, while 16 and 160 nM lectin was used for all other H and B type 1 contents, respectively. The time 
axis has been set to zero at the moment of noroVLP injection. SLB formation prior to the noroVLP 
binding is shown in Figure S1 in the Supporting Information. (d) Initial binding rates were determined 
from the binding curves shown in Figure S1 based on a linear fit of the phase of linear decrease of ∆f. 
This yields noroVLP binding rates in terms of the rate of the resonance frequency shift, d∆f/dt, versus 
the total GSL concentration in the SLB.32 
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Subsequent injection of a competitive ligand, here a fucose-binding lectin isolated from 
bacterium Ralstonia solanacearum, to noroVLP-engaged SLBs causes an overall decrease in ∆D 
(damping), which is indicative for a release of the SLB-bound noroVLPs (Figure 1b and c).6 
Interestingly, the kinetics of the process varies with the total GSL concentration within the SLB. For 
example, upon lectin addition to a noroVLP-covered SLB, we observed an initial mass loss (increase 
in ∆f) followed by a mass uptake (decrease in ∆f) at < 3.9 mol% H type 1, whereas the kinetics is 
somewhat more complex at 3.9 mol% and above (Figure 1b and S2a). In the case of B type 1, the 
VLP release kinetics appear to be very similar, but the transitions are shifted towards lower 
concentrations of B type 1 in the SLB (Figure 1c and S2b). As discussed further below, to obtain the 
virus release kinetics within a similar timescale a ten times higher concentration of lectin was used in 
the case of B type 1 compared to the case of H type 1. 
Upon inspection of the frequency traces recorded at high GSL concentrations (3.5 mol% B type 
1 and 6.3 mol% H type 1, respectively), it becomes clear that before lectin binding starts to induce 
noroVLP release, there is a mass uptake (drop in Df) without any substantial change in ∆D (see dash-
dotted lines in Fig. 1b, c and Fig. 2a, c). Supported by the fact that lectin binding to GSL-containing 
SLBs does not induce appraisable changes in damping (see Figure S3), this mass uptake indicates 
binding of lectins to the SLB that is not associated with release of noroVLPs, i.e., lectins binding to 
free GSLs in the bilayer (not being engaged in noroVLP attachment). As described previously,6 an 
insignificant change in DD upon competitive binding with different DD and Df signatures, makes it 
possible to deconvolute the measured frequency trace into two separate frequency traces representing 
the binding kinetics of noroVLPs and lectin, respectively (Figure 2). Further results of this 
deconvolution procedure are shown in Figures S5 and S7, demonstrating that lectin addition 
eventually leads to complete release of the SLB-bound noroVLPs irrespective of the H type 1 or B 




Figure 2. Deconvolution of the measured frequency trace (black line) of noroVLPs bound to a SLB 
containing (a) 6.3 mol% H type 1 and (b) 3.5 mol% B type 1 at competitive binding. 0.25 nM 
noroVLP was employed for the virus particle binding. 16 and 160 nM lectin was added to induce 
competition in case of H and B type 1, respectively. The green line corresponds to the measured 
dissipation shift, which was used to deconvolute the frequency trace into the contributions causes by 
noroVLPs (red line) and lectin (blue line), respectively (see Supporting Information for details). (c, 
d) Comparison of lectin traces that have been extracted from the competition experiments (blue) with 
those that have been recorded for lectin binding to a bare GSL-containing SLB (i.e., in absence of 
noroVLPs; orange). 
In order to probe if the presence of noroVLPs modifies the attachment kinetics of the lectin, 
Figures 2c and d compares lectin traces that have been extracted from the competition experiments 
(blue trace) with those that have been recorded for lectin binding to a bare GSL-containing SLB (i.e., 
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in absence of noroVLPs; orange trace). Further examples are given in Figure S5 and S7. Inspection 
of Figures 2c and d suggests that the lectin binds slightly faster to SLBs being incubated with 
noroVLPs and that the presence of SLB-bound noroVLPs also increases the final lectin surface 
coverage (indicated by the lower Df values at saturation; Figure S6). Two plausible explanations of 
this increased lectin surface coverage are: i) the lectins bind with lower valency to the GSLs in the 
presence of noroVLPs, e.g. due to the induction of conformational changes or an increased bilayer 
tension close to the noroVLPs, thereby allowing more lectins to bind to the same amount of GSLs, 
and ii) noroVLP-binding promotes transfer of GSLs from the lower to the upper leaflet of the SLB. 
Owing to the large HBGA structure presented by the GSLs, the latter explanation may appear unlikely 
at first sight, but has in fact already been observed for other multivalent binders (cholera toxin subunit 
B interacting with the ganglioside GM1)33. Interestingly, accounting for an apparent increase in GSL 
concentration by matching the saturated surface coverage of lectin in both cases (noroVLP–free 
versus noroVLP–engaged SLB), resulted in an almost perfect superposition of the corresponding 
lectin binding kinetics (Figure S5 and S7), leading to ‘effective’ total GSL concentration of 6.8 
instead of 6.3 mol% H type 1, 3.8 instead of 3.5 mol% B type 1 and so forth. 
To compare the noroVLP release kinetics independent of the total GSL concentration used in 
the experiment, the deconvoluted frequency traces of noroVLP and lectin were normalized with 
respect to their corresponding maximum surface coverage (DfN,max and DfL,max in Figure 2; see 
Supporting Table S1 for the determined values). Plotting the normalized surface coverage of 
noroVLPs, DfN(t)/DfN,max, versus the one of the lectin, DfL(t)/DfL,max, allows for assessing the effect of 
successive GSL depletion (caused by lectin addition) on noroVLP release (Figures 3a and b). The 
release of noroVLPs follows a sigmoidal curve in dependence of the normalized lectin surface 
coverage, the inflection point of which shifts to larger DfL/DfL,max values for an increasing total GSL 
concentration. This indicates that increasing the total GSL concentration in the SLBs allows more 
lectins to bind to the SLB before noroVLP release becomes triggered by competition. In order to 
better understand this effect, we first calculated the fraction of GSLs that are not engaged in lectin 
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binding. The fraction can be expressed by 1 – DfL/DfL,max, as the saturated lectin coverage increases 
approximately linearly with GSL concentration up to 6.3 mol% H Type 1 and 1.4 mol% B type 1 
(deconvoluted lectin coverages in Figure S7). This fraction is expressed with respect of the total GSL 
concentration embedded in the SLB. Thus, multiplying 1 – DfL/DfL,max by the ‘effective’ total GSL 
concentration (discussed above) yields the concentration of GSLs not being bound to a lectin (in units 
of mol%). Interestingly, upon plotting the noroVLP release versus the total GSL concentration that 
is not engaged in lectin binding, the corresponding release curves superimpose in case of H type 1 
(Figure 3c, circles). In contrast, the noroVLP release curves show minor yet significant deviations for 
B type 1 (Figure 3d, circles). 
In analogy to Figure 1d, the inflection point of these release curves can be used to determine 
the concentration of GSLs (not being engaged in lectin binding) below which noroVLP release is 
triggered. This critical GSL concentration for release depends, in contrast to the one of Figure 1d, on 
various parameters, such as the surface coverage of noroVLPs prior to lectin competition and the 
minimum number of GSLs that have to be bound to a noroVLP to achieve sufficiently firm attachment 
on a SLB. Nevertheless, Figure 3c shows two superimposing release curves, which indicates that the 
critical GSL concentration (3 mol%) of release does not depend on the total GSL concentration in the 
SLB for H type 1. Furthermore, the critical GSL concentration for H type 1 is only 10% larger than 
the concentration of the same GSL needed to achieve noroVLP attachment (Figure 3d, solid line 
versus circles; the solid line has been taken from the fit of Figure 1d). Release from B type 1 shows 
a fundamentally different behavior (Figure 3d, solid line versus circles). Here, the critical GSL 
concentration for release (~0.4 mol%; Figure 3d, circles) is always significantly smaller than the B 




Figure 3. Lectin coverage dependent detachment of SLB-bound noroVLPs. (a, b) A comparison of 
the relative surface coverages of noroVLPs, DfN/DfN,max, and lectin, DfL/DfL,max, at nominal GSL (H or 
B type 1) concentrations as indicated. (c, d) The relative noroVLP surface coverage (DfN/DfN,max) 
versus the concentration of GSLs in the SLB that are not engaged in binding to lectins (mol% GSLnoLec 
in SLB; see main text for details). The solid line in Figure 3c and d is a sigmoidal fit of the noroVLP 
attachment rate vs. GSL concentration in SLB as plotted in Figure 1d. 
 
Discussion and Conclusion	 
Using a GSL-containing SLB as model lipid membrane, we have explored the attachment of 
noroVLPs to two different GSLs, H type 1 and B type 1, respectively, and the detachment of SLB-
bound noroVLPs caused by addition of a lectin from Ralstonia solanacearum. Monitoring the 
attachment process using QCM-D allowed us to quantify the binding rate of noroVLPs as a function 
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of GSL type and concentration. The observed binding rate increased with increasing GSL 
concentration, showing a sigmoidal curve (as often observed when probing multivalent interactions 
6, 11, 34-35) with an inflection point at around 3 mol% H type 1 and 0.5 mol% B type 1. We attribute this 
large deviation in the inflection points to a much larger affinity of noroVLPs to B type 1 than to H 
type 1, despite the very small structural difference of these GSLs. Accounting for the fact that the 
head group area of a single phosphocholine lipid is approximately 0.64 nm²	 (see Ref. 36), GSL 
concentrations of 0.5 and 3 mol % correspond to densities of 0.008 and 0.047 GSLs per nm², 
respectively. This shows that noroVLPs only bind to H type 1-containing SLBs, if the H type 1 surface 
density (0.047/nm²) approaches the density of the HBGA binding pockets on the noroVLP capsid 
(0.035 or 0.071/nm² using the one- or two-binding site model29-30, respectively). In contrast, binding 
to B type 1 requires only one-tenth of this density to achieve notable binding rates, which clearly 
indicates that the noroVLP interaction with H type 1 GSLs is much weaker than that to B type 1. 
We also quantified the release of GSL-bound noroVLPs by addition of a lectin, and used a 
deconvolution method to separate the detachment kinetics of noroVLPs from the lectin attachment 
kinetics from the measured QCM-D traces for both GSL types and at various GSL concentrations. 
As the lectin has different binding kinetics (affinity) towards the two GSLs, which may influence the 
observed differences in the noroVLP release kinetics, a direct comparison of the correspondingly 
measured and deconvoluted release kinetics was not straightforward. To address this challenge, we 
used the lectin surface coverage to calculate (during competition) the concentration of GSLs that are 
not engaged in lectin binding, GSLnoLec, and correlated the noroVLP surface coverage with GSLnoLec 
(Figures 3c and d). Similar to Figure 1d, the noroVLP surface coverage exhibits a sigmoidal 
dependence on GSLnoLec and showed that release of noroVLPs is induced at low GSLnoLec values. 
Interestingly, the traces of the H type 1 measurements overlap very well in this plot, despite the 
appreciable difference in total GSL concentration used. Furthermore, the inflection point of these 
traces, i.e., the GSLnoLec concentration below which release of noroVLPs is induced, is only 10% 
larger than the corresponding inflection point in Figure 1d. This shift can be attributed to the fact that 
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the abscissa, GSLnoLec, in Figure 3c represents the concentration of GSLs not being engaged in any 
binding (“free GSLs”) plus the concentration of noroVLP-bound GSLs, while in Figure 1d only the 
concentration of free GSLs is shown (as the initial binding rate was determined at the beginning of 
the binding process, i.e., at negligible noroVLP surface coverage). Hence, even under GSL-VLP 
attachment equilibrium conditions, the release curves of Figure 3c are expected to be shifted to higher 
concentrations with respect to the binding rate curves of Figure 1d, which expresses the minimum 
GSL concentration required for a firm attachment of noroVLPs on SLB.  
Interestingly, noroVLP release from B type 1 showed a fundamentally different behaviour, as 
all release curves yielded inflection points at lower concentrations with respect to the corresponding 
binding rate curve of Figure 1d, a feature that cannot be explained by differences in noroVLP surface 
coverage (see Figure 1c). Additionally, as GSLnoLec represents the sum of free and noroVLP-engaged 
GSLs, the actual concentration of free B type 1 GSLs in the SLB is even lower than indicated by the 
x-axis of Figure 3d. This means that release of noroVLPs from B type 1 occurs at free B type 1 
concentrations that are far below the concentration needed to achieve initial noroVLP attachment to 
the SLB (Figure 1d). In other words, once bound to a B type 1-containing SLB, the noroVLPs are 
able to remain firmly attached to the SLB even at GSL concentrations at which they would not be 
able to initiate firm attachment from solution. This clearly indicates that the noroVLPs accumulate B 
type 1 GSLs in the interaction area with the SLB, i.e., the total GSL concentration (free plus noroVLP-
engaged) is larger in the noroVLP-SLB interaction area than in SLB areas not being engaged in 
noroVLP interactions. Such an accumulation cannot be ruled out for the interaction with H type 1 
GSLs, but it has to be much smaller in comparison to B type 1 GSLs. This is consistent with their 
large difference in affinity towards noroVLPs, since a higher affinity of the noroVLP towards  
B type 1 may favour accumulation of GSLs underneath the SLB-bound viruses. 
Irrespective of some variance in the inflection point of the B type 1 release curve, it is evident 
from Figure 3c and d that release of noroVLPs occurs at much lower GSLnoLec values for B type 1 
	 16	
compared with H type 1. In analogy to the binding rate curves, this again indicates that noroVLPs 
have a higher affinity towards B type 1 than to H type 1. This finding is supported by the energy of 
single noroVLP-GSL bond determined from the competitive release kinetics at 6.3 mol% H type 1 
and 3.5 mol% B type 1, respectively, at which the noroVLP surface coverage is far from saturation. 
The corresponding estimates were done analytically as earlier described in detail in the case of the 
interaction of SV40 with the lipid GM1.6 As input, we need the maximum number of the ligand-
receptor bonds in the contact zone, the release time scale, and the scale of the fraction (or 
concentration) of unbound GSL (with respect to the total number of lipids in SLB) during the release. 
Calculating with 360 binding sites per VLP, the maximum number of bonds, n @ 12, was obtained by 
taking the norovirus geometry (or, more specifically, the virus radius and the area of the binding sites) 
into account as it was earlier done for noro- and SV40 viruses.4,6 The release time scale, τ = 5 and 10 
min (in the cases of H type 1 and B type 1, respectively), was estimated from the kinetics measured 
(Figure 2a and b). The fraction of unbound GSL, θun = 0.03 and 0.004 (H type 1 and B type 1), was 
estimated on the basis of the release (or attachment) kinetics (e.g., Figure 3c and d). With this input, 
we obtained (see Section “Estimation of the GSL-noroVLP binding energies” in the Supporting 
Information) that the single noroVLP-H type 1 and B type 1 bond energies are ∼ 3.5 and 4.5 kcal/mol, 
respectively. The sensitivity of the estimates of this energy to the input parameters, τ and θun,  is 
logarithmically weak. For this reason, the difference in the energies is small. Calculating with 180 
binding sites, which is a relevant comparison,37 instead yields a maximum number of bonds of n @ 6, 
leading to bond energies of ∼ 5 and 6 kcal/mol, respectively. 
The extracted binding energies are very similar (360 binding site model) to, and a factor of 2 larger 
(180 binding site model) than, the values reported in a recent study,37 in which Kd values for the 
interaction of noroVLP P-dimers with methyl α-l-fucopyranoside or the blood group B trisaccharide 
α-l-Fuc-(1,2)-[α-d-Gal-(1,3)-]-α-d-Gal-(1,N)-N3 have been determined using NMR. The good 
agreement with literature values could be taken as indication that the 360 binding site model is more 
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likely to represent the binding mode of noroVLPs towards GSLs. We cannot exclude, however, that 
deviations in the extracted binding energies can be attributed to the fact that different carbohydrates 
were used in the NMR and QCM-D experiments: While (water soluble) methyl α-l-fucopyranoside 
and a blood group B trisaccharide were used in the NMR study, complete GSLs were used in our 
QCM-D study, presenting either a penta- (H type 1) or hexasaccharide (B type 1), respectively. Hence, 
minor differences in the binding energies are here not sufficient to generally rule out the 
appropriateness of the 180 binding site model, as these differences may simply reflect differences in 
the structure of the used carbohydrates. In fact, molecular dynamics simulations with the VA387 
GII.4 B-trisaccharide co-crystal structure have suggested that the binding strength is increased when 
the trisaccharide is extanded to the B type 1 tetrasaccharide.38 
Furthermore, the above-mentioned NMR study37 also shows that the unusual binding behaviour of 
noroVLPs to HBGAs, which has led to the identification of the second fucose binding site of VP1, 
can be related to a spontaneous deamidation of an asparagine residue in the HBGA binding pocket. 
This study therefore suggests that the second fucose binding site is only of minor importance in 
HBGA binding of the GII.4 strain and makes the 180 binding site model more realistic.37 We therefore 
decided to provide the binding energies extracted using both models, as the 360 binding site model 
is in better agreement with reported values, while the 180 binding site model is better supported by 
recent biochemical characterizations of the VP1-HBGA interaction.37 
It is important to note that the HBGA binding pocket lowers its ability to bind HBGAs upon 
spontaneous deamidation of the asparagine residue, a process that has a half-time of 1.5 days at 
37°C.37 Although we cannot rule out the occurrence of spontaneous deamidation during the 
production of our noroVLPs, a process which would reduce the effective number of binding sites 
below 180 or 360 per noroVLP, respectively, we can rule out any significant impact of deamidation 
during noroVLP storage (at 4°C) or the biophysical characterization using QCM-D (at room 
temperature). This follows from the observation that we did not observe significant changes between 
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identical QCM-D measurements performed within a period of 3 months and as the timescale of a 
QCM-D experiment is on the order of few hours (in contrast to the half-time of 1.5 days reported for 
the spontaneous deamidation). Hence, the reported binding energies should be understood as lower 
limits, as deamidation cannot be fully ruled out and would reduce the number of available binding 
sites per noroVLP. 
Compared to our previous study of the competition for GSLs between SV40 and recombinant 
cholera toxin B subunit, in which we quantified the bond energy of SV40-GSL from the virus release 
kinetics,6 the data of the present study demonstrate in addition that the noroVLP binding 
affinity/strength towards different GSLs can be compared by analyzing either their binding kinetics 
to a GSL-containing SLB or their release kinetics from the lectin-induced by competition. In the 
former case, the GSL concentration at the transition from reaction- to diffusion-limited binding 
kinetics of noroVLP reflects the binding strength of noroVLPs to the different GSLs: A decrease in 
transition concentration indicates an increase in the binding strength of the noroVLP towards the 
particular GSL. However, experiments using multiple SLBs with different GSL concentrations is 
required to obtain such transition curves, which may in addition suffer from uncertainties, particularly, 
with respect to handling low GSL concentrations such as in case of B type 1. In contrast, in the 
competition approach a single kinetic measurement per GSL type is sufficient to qualitatively 
compare the binding strength of noroVLPs towards different GSLs, provided that the noroVLP 
coverage before injecting the lectin is above the detection limit and similar in the corresponding 
measurements (see Figure 1). The general relevance of this approach is obvious from the fact that 
conceptually identical analysis can be done for a range of norovirus attachment factors with a 
difference in the binding affinity even lower than that of B and H type 1, and also for any virus for 
which competitive binding can be experimentally realized. This typically only requires the existence 
of a second species (e.g., a lectin in the current case), which possesses binding sites with higher 
binding affinity to the receptors/attachment factors than the ones of the virion/VLP; an exact 
knowledge of the involved affinities is not required. 
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In addition to an intrinsic interest, the competitive binding under consideration is also useful in 
the context of quantification the strength of the ligand-receptor bonds responsible for the interaction 
of viruses with lipid membranes or, more specifically, in the context of the development of inhibitors 
targeting either viruses12, 39-40 or their receptors/virus attachment factors.15-16, 41 These inhibitors aim to 
block the virus attachment on cell membranes and to do so they need a sufficiently high 
affinity/binding strength towards the target. Unlike monovalent ligand-receptor interactions, virus-
receptor interactions on cell-membranes are typically multivalent. Under this condition, 
thermodynamic methods such as ITC can provide the binding affinity/energy of a single virus-
receptor bond, but they are unable to evaluate the absolute binding strength of viruses being attached 
to the membrane-embedded ligands. In this regard, surface-based kinetic assays better represent the 
native plasma membrane environment. In these assays, the ratio of association (kon) and dissociation 
(koff) rate constant upon virus binding to receptors tethered to the surface or embedded in lipid-
membrane represents the dissociation constant (Kd) of the virus-receptor pair, a measure of the 
binding affinity. Although single virus-receptor bonds are assumed to form and dissociate 
continuously, the cumulative effect from the multivalent interaction makes the virus attachment to 
appear irreversible. This hinders determination of koff and thereby Kd. Diminishing the multivalent 
interaction by lowering the receptor density leads to a transient binding with weak association rate, 
which becomes difficult to quantify with standard experimental techniques. In contrast, the 
competition approach used here may still be operative to probe both attachment and detachment 
kinetics of viruses on membranes and thereby, for the determination of their relative binding 
affinity/energy. 
Finally it is worth emphasizing that at native conditions, the receptor/attachment factor 
concentration in the plasma membrane influences the absolute binding strength of viruses, as 
indicated by in vivo studies of infection susceptibility of other caliciviruses.42 At cellular infection, 
the virus coverage on the plasma membrane is likely to be far from saturation and membrane receptors 
are typically in excess. These conditions are suitable for both comparative and quantitative analysis 
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of competition kinetics. Hence, our approach to scrutinize multivalent virus-receptor interactions 
might be applicable also beyond the model systems used in this work. This aspect is obviously 
particularly useful in screening for new receptors of emerging strains of highly mutating viruses, such 
as human norovirus, as well as for the development of antiviral drugs. 
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